Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up.
ADPKD
inflammation
kidney transplantation
lymphopenia
white blood cells
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
17
03
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Autosomal dominant polycystic kidney disease (ADPKD) has occasionally been associated with lower peripheral white blood cell (WBC) counts. This study aimed to investigate the peripheral blood cell counts in a large cohort of kidney transplant recipients before and after kidney transplantation and its potential impact on post-transplant outcomes. This was a retrospective study with long-term follow-up data of 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals, of whom 392 had ADPKD. In total, 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals were included, of whom 392 had ADPKD. Both pre- and post-transplantation, ADPKD patients had significantly lower total WBC counts, and more specifically lower neutrophil, lymphocyte and eosinophil counts compared with the non-ADPKD patients. This observation was independent of potential confounders such as level of inflammation, smoking habit, vitamins and pre-transplant medication. Overall survival and kidney transplant survival were significantly better in ADPKD vs non-ADPKD transplant recipients and a longer time to first infection was observed. However, no association between blood cell counts and outcome differences was found. In conclusion, this large single-center study reports a strong and independent association between ADPKD and lower peripheral WBC counts both before and after kidney transplantation. Considering the role of inflammation in disease progression, further investigation into the role of WBC in ADPKD is needed.
Sections du résumé
Background
UNASSIGNED
Autosomal dominant polycystic kidney disease (ADPKD) has occasionally been associated with lower peripheral white blood cell (WBC) counts. This study aimed to investigate the peripheral blood cell counts in a large cohort of kidney transplant recipients before and after kidney transplantation and its potential impact on post-transplant outcomes.
Methods
UNASSIGNED
This was a retrospective study with long-term follow-up data of 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals, of whom 392 had ADPKD.
Results
UNASSIGNED
In total, 2090 patients who underwent a first kidney transplantation in the Leuven University Hospitals were included, of whom 392 had ADPKD. Both pre- and post-transplantation, ADPKD patients had significantly lower total WBC counts, and more specifically lower neutrophil, lymphocyte and eosinophil counts compared with the non-ADPKD patients. This observation was independent of potential confounders such as level of inflammation, smoking habit, vitamins and pre-transplant medication. Overall survival and kidney transplant survival were significantly better in ADPKD vs non-ADPKD transplant recipients and a longer time to first infection was observed. However, no association between blood cell counts and outcome differences was found.
Conclusions
UNASSIGNED
In conclusion, this large single-center study reports a strong and independent association between ADPKD and lower peripheral WBC counts both before and after kidney transplantation. Considering the role of inflammation in disease progression, further investigation into the role of WBC in ADPKD is needed.
Identifiants
pubmed: 38046014
doi: 10.1093/ckj/sfad165
pii: sfad165
pmc: PMC10689124
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2578-2586Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
The research activities described in this manuscript are supported by Otsuka and Sanofi. Pieter Schellekens is supported by the Research Foundation Flanders (F.W.O.). EVL, holds a fellowship grant (1143919N) from The Research Foundation Flanders (F.W.O). DM reports research grants from Otsuka and serves in advisory boards for Otsuka, Sanofi Genzyme and Reata, all outside the submitted work and all paid to her institutions UZ Leuven and KU Leuven, Belgium.
Références
Platelets. 2016;27(3):262-3
pubmed: 26270278
Transpl Int. 2011 Jun;24(6):582-7
pubmed: 21352383
Toxins (Basel). 2012 Oct 24;4(11):962-90
pubmed: 23202302
Clin Radiol. 2019 Dec;74(12):975.e17-975.e24
pubmed: 31563290
PLoS One. 2018 May 8;13(5):e0196684
pubmed: 29738538
PLoS Med. 2018 Nov 1;15(11):e1002685
pubmed: 30383787
Platelets. 1995;6(6):336-9
pubmed: 21043761
Nat Rev Nephrol. 2019 Jul;15(7):412-422
pubmed: 30948841
Blood Purif. 2011;32(1):69-74
pubmed: 21346339
Cell Signal. 2020 Sep;73:109647
pubmed: 32325183
Exp Clin Transplant. 2015 Oct;13(5):413-20
pubmed: 26450465
Nephron. 2002 May;91(1):175-6
pubmed: 12021540
Transpl Int. 2010 Sep;23(9):878-86
pubmed: 20230542
FASEB J. 2004 May;18(7):884-6
pubmed: 15001556
Lancet. 2007 Apr 14;369(9569):1287-1301
pubmed: 17434405
BMC Nephrol. 2019 Sep 13;20(1):355
pubmed: 31514750
Pediatr Nephrol. 2021 Nov;36(11):3505-3514
pubmed: 33502599
Transplant Proc. 2019 Jul - Aug;51(6):1810-1815
pubmed: 31256873
Nephrol Dial Transplant. 2018 Mar 1;33(3):489-496
pubmed: 28387829
Clin Infect Dis. 2012 Sep;55(5):679-86
pubmed: 22610926
PLoS One. 2014 Apr 18;9(4):e93674
pubmed: 24747723
Nephrol Dial Transplant. 2016 Mar;31(3):487-95
pubmed: 26492923